Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer
2019
Real-world evidence derived from electronic health records (EHRs) is increasingly recognized as a supplement to evidence generated from traditional clinical trials. In oncology, tumor-based
Response Evaluation Criteriain
Solid Tumors(RECIST) endpoints are collected in clinical trials. The best approach for collecting similar endpoints from EHRs remains unknown. We evaluated the feasibility of a traditional RECIST-based methodology to assess EHR-derived real-world progression (rwP) and explored non-RECIST-based approaches. In this retrospective study, cohorts were randomly selected from
FlatironHealth database of patient-level EHR data in advanced non-small cell lung cancer. A RECIST-based approach was tested for feasibility (N=26). Three non-RECIST abstraction approaches were tested for feasibility, reliability, and validity (N=200): (1)
radiology-
anchored, (2) clinician-
anchored, and (3) combined. RECIST-based cancer progression could be ascertained from the EHRs of 23% of patients (6/26). In 87% of patients (173/200), at least one rwP event was identified using both the
radiology- and clinician-
anchoredapproaches. rwP dates matched 90% of the time. In 72% of patients (124/173), the first clinician-
anchoredrwP event was accompanied by a downstream event (e.g., treatment change); the association was slightly lower for the
radiology-
anchoredapproach (67%; 121/180). Median overall survival (OS) was 17 months (95% confidence interval [CI]: 14, 19). Median real-world progression-free survival (rwPFS) was 5.5 (95% CI: 4.6, 6.3) and 4.9 months (95% CI: 4.2, 5.6) for clinician-
anchoredand
radiology-
anchoredapproaches, respectively. Correlations between rwPFS and OS were similar across approaches (Spearmans rho: 0.65-0.66). Abstractors preferred the clinician-
anchoredapproach as it provided more comprehensive context. RECIST cannot adequately assess cancer progression in EHR-derived data due to missing data and lack of clarity in
radiologyreports. We found a clinician-
anchoredapproach supported by
radiologyreport data to be the optimal, and most practical, method for characterizing tumor-based endpoints from EHR-sourced data.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
18
References
1
Citations
NaN
KQI